What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
Prevail (flunixin meglumine 50 mg/mL) is a potent, non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity.
Flunixin meglumine is an analgesic, nonsteroidal, non-narcotic, and powerful agent that boasts antipyretic and anti-inflammatory benefits. It is far more powerful than codeine, meperidine, and pentazocine as an analgesic.
Horse: Prevail™ is recommended for the alleviation of inflammation and pain associated with musculosk-eletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.
Cattle: Prevail™ is indicated for the control of pyrexia associated with bovine respiratory disease and endotoxemia. Prevail™ is also indicated for the control of inflammation in endotoxemia.
Horse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL/100 lbs) of bodyweight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.The recommended dose for the alleviation of pain asso-ciated with equine colic is 0.5 mg per pound of body-weight. Intravenous administration is recommended forprompt relief. Clinical studies show pain is alleviated inless than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical stud-ies approximately 10% of the horses required one or two additional treatments.The cause of the colic should be determined and treated with concomitant therapy.
Cattle: The recommended dose for cattle is 1.1 to 2.2 mg/kg (0.5 to 1mg/lb; 1 to 2 mL per 100 lbs) given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12 hour intervals for up to 3 days.The total daily dose should not exceed 2.2 mg/kg (1.0 mg/lb) of bodyweight.Avoid rapid intravenous administration of the drug.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Horse: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine.
Cattle: There are no known contraindications to this drug in cattle when used as directed. Do not use in animals showing hypersensitivity to flunixin meglu-mine. Use judiciously when renal impairment or gastric ulceration are suspected.
Cattle must not be slaughtered for hu-man consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food.Not for use in dry dairy cows.A withdrawal pe-riod has not been established for this prod-uct in preruminating calves.Do not use in calves to be processed for veal. Not for use in horses intended for food.
As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sen-sitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renaltoxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular,and/or hepatic dysfunction.
Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of Pre-vail™ with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.
Horse: The effects of Prevail™ on pregnancy has not been determined. Studies to determine activity of Prevail™ when administered concomitantly with other drugs have not been conducted. Drug compat-ibility should be monitored closely in patients requiring adjunctive therapy.
Cattle: Do not use in bulls intended for breeding, as reproductive effects of Prevail™ in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle.There may be a delay in the onset of estrus if flunixin is administered during the prostaglan-din phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the poten-tial to delay parturition through a tocolytic effect. Do not exceed the recommended dose.
Horse: A 3-fold intramuscular dose of 1.5mg/lb of bodyweight daily for 10 consecutive days was safe. No changes were observed in hematology, serum chemistry, or urinalysis values. Intravenous dosages of0.5mg/lb daily for 15 days; 1.5mg/lb daily for 10 days; and 2.5mg/lb daily for 5 days produced no changes inblood or urine parameters. No injection site irrita-tion was observed following intramuscular injection of the 0.5mg/lb recommended dose. Some irritation was observed following a 3-fold dose administeredintramuscularly.
Cattle: No flunixin-related changes (adverse reactions)were noted in cattle administered at 1X (2.2 mg/kg;1.0 mg/lb) dose for 9 days (three times the maximumclinical duration). Minimal toxicity manifested itself atmoderately elevated doses (3X and 5X) when flunixin was administered daily for 9 days, with occasional findings of blood in the feces and/or urine. Discontinue use if hematuria or fecal blood are observed.
In horses, isolated reports of local reactions follow-ing intramuscular injection, particularly in the neck, have been received.These include localized swelling,sweating, induration, and stiffness. In rare instances inhorses, fatal or nonfatal clostridial infections or other infections, have been reported in association withintramuscular use of Prevail™. In horses and cattle,rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.
Store between 2° and 30°C (36° and 86°F).